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ABSTRACT 
 
 The relative contributions of cyclooxygenase-1 (COX-1) versus COX-2 to 
vascular biosynthesis of prostacyclin (PGI2) and thromboxane (TxA2) and the role of 
estrogen in the regulation of COX function were studied in the thoracic aorta of age-
matched 14-16 week old female (F) and male (M) Sprague Dawley rats. We 
hypothesized that COX-1 and COX-2 contribute differentially to the synthesis of PGI2 
and TxA2 in the presence of estrogen. Ovary intact (Int-F), ovariectomized (OvX-F) and 
OvX+estrogen-replaced (OvX+ER-F) rats were studied. Rats were sacrificed 14 days 
post-op, and 3mm aortic rings were incubated in Krebs-Henseleit-bicarbonate buffer 
(KHB), containing either vehicle (basal), vasopressin (VP, 10-6 M), VP+SC-560 (SC, 
selective COX-1 inhibitor, 10-7 M), or VP+NS-398 (NS, selective COX-2 inhibitor, 10-5 
M). The KHB was analyzed by specific radioimmunoassays (RIA) for 6-keto-PGF1α 
(stable metabolite of PGI2) and TxB2 (stable metabolite of TxA2). Basal PGI2 was 
similar in M and all F groups (P=0.19). VP-stimulated PGI2 in M (4,528 ± 745) and 
OvX-F (4,785 ± 773) was reduced similarly by SC and NS (P>0.05). Also, VP-
stimulated PGI2 in Int-F (15,352 ± 2,209) and OvX-ER-F (13,053 ± 3,086) was reduced 
significantly by SC and NS (P<0.05). Basal TxA2 was similar in all groups (P>0.05). 
VP-stimulated TxA2 in M (30 ± 4) and OvX-F (31 ± 7) was reduced similarly by SC and 
NS (P>0.05). VP-stimulated TxA2 in OvX-ER-F (71 ± 7) was reduced markedly more 
by NS than by SC (P<0.05). In conclusion, these data suggest that: 1) in the absence of 
estrogen in OvX-F and M, both PGI2 and TxA2 are derived equally from COX-1 and 
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COX-2; and 2) in Int-F and OvX-ER-F, estrogen markedly enhances PGI2 and TxA2 
production, primarily by upregulating COX-2 function.  
 Furthermore, the mechanism by which TxA2 inhibits PGI2 synthesis was 
investigated in M rats. It was hypothesized that TxA2 inhibits PGI2 through a PKC-
mediated nitrosylation on PGI synthase. Aortic rings were prepared and incubated in 
KHB, containing either vehicle (VP, 10-6 M), Calphostin C (CAL; PKC inhibitor, 10-
6M), or Furegrelate (FUR; TP receptor antagonist; 50µM), Ridogrel (RID; combined TP 
receptor antagonist and TxS inhibitor; 10-5M), or Dazoxiben (DAZ; 50µM). The KHB 
was analyzed by specific RIA for 6-keto-PGF1α and TxB2. TxA2 release was 
significantly attenuated by DAZ, RID, and FUR but was markedly enhanced by CAL 
228% (0.001<P<0.05). Despite Ridogrel and Furegrelate significantly decreasing TxA2 
release, neither of these inhibitors significantly attenuated PGI2 release in the aorta 
(P>0.05). However, PGI2 release was enhanced 158% in the presence of DAZ 
(0.001<P<0.05). It is possible that Calphostin may inhibit a PKC-mediated homologous 
desensitization loop to increase TxA2 release. DAZ effects clearly show that TxS 
inhibitors increase PGI2 release, however, it is puzzling that Ridogrel did not have the 
same effect. While TxA2 does seem to have a depressing effect of PGI2, it is clear that 
PKC-mediated nitrosylation of PGI synthase is not the mechanism by which TxA2 
inhibits PGI2 release. 
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CHAPTER I  
INTRODUCTION 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) comprise a therapeutic class of 
drugs, which exhibit anti-inflammatory, analgesic and antipyretic properties. In 1899, 
Bayer introduced the first mass-produced drug to treat pain, inflammation and fever - 
acetylsalicyclic acid, known as aspirin. Aspirin, one of the most widely used and 
marketed drugs in the pharmaceutical industry, has been celebrated in recent years as 
being cardioprotective when taken daily. The novel use of NSAIDs as prevention from 
certain cardiovascular diseases (CVD) could potentially change the fate of millions of 
people. The World Health Organization (WHO) estimates that CVD is the single largest 
contributor to global mortality, and will continue to be so for decades to come (2). In 
2008, CVDs accounted for 17 million deaths, contributing to 48% of all deaths from 
non-communicable diseases. It is expected that by 2015, CVDs will be responsible for 
20 million deaths (30% of all deaths) worldwide (27). Thus, aspirin and other NSAIDs 
could play an important role in the future of CVD prevention.  
A subgroup of NSAIDs, the COX-2 selective inhibitors (COXIBS), appear to 
have a paradoxical deleterious effect on the cardiovascular system, and several of these 
were removed from the market by the FDA due to an increased risk of thrombosis 
associated with their use. The use of NSAIDs, and their effects on the cardiovascular 
system, is much more complicated than first acknowledged. The effects that NSAIDs 
have on the cardiovascular system is based on the inhibition of two functionally 
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antagonistic prostanoid mediators produced in the vascular wall (the vasodilator, 
prostacyclin (PGI2) and the vasoconstrictor, thromboxane (TxA2)) therefore disrupting 
the normal levels in the body. The specific effects of NSAIDs on the balance of 
prostanoids in the cardiovascular system have yet to be clearly elucidated.  
Normal homeostasis within the vascular system relies upon the balance of PGI2 
vs. TxA2 production. Therapeutic use of NSAIDs to inhibit the enzymes cycloxygenase 
(COX)-1 and/or COX-2, the rate-limiting enzyme for prostanoid synthesis, causes an 
alteration in the homeostatic balance between levels of PGI2 and TxA2. The imbalance 
theory is widely quoted and describes a negative shift in the release of vascular 
prostanoids, resulting in platelet aggregation and thrombosis. However, the principal 
studies upon which this theory is based are flawed, because urinary metabolites of PGI2 
do not provide an accurate measurement of vascular prostacyclin production.  
Sexual dimorphism in prostanoid synthesis exists, but is largely ignored in 
vascular physiology. Estrogen enhances the biosynthesis of thromboxane through 
upregulation of COX-2 and thromboxane synthase expression. Therefore, the relative 
roles of COX-1 vs. COX-2 in the biosynthesis of PGI2 and TxA2 by the vascular wall 
were investigated by using specific COX-1 and COX-2 inhibitors. The thoracic aortas of 
both male and female rats were studied in order to elucidate sex differences that may 
exist due to the presence or absence of estrogen.  
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CHAPTER II  
LITERATURE REVIEW 
 
2.1 Cyclooxygenase and Arachidonic Acid Metabolism   
The first NSAID discovered, aspirin, was produced over a hundred years ago 
from a component in willow bark into acetylsalicylic acid for the treatment of arthritis 
pain. However, the mechanism of action of NSAIDs was not discovered until the 1960’s 
when Sir John Vane determined that the mechanism of action was inhibition of the 
enzyme cyclooxygenase (COX), which plays a central role in the metabolism of 
arachidonic acid and the synthesis of prostanoids. The metabolism of arachidonic acid 
(AA) into its functional components follows a well-established pathway. Arachidonic 
acid, a fatty acid present in phospholipids of cell membranes, is released from the cell 
membrane by the action of phospholipase A2 (PLA2) or diacylglycerol (DAG) lipase in 
response to a number of stimuli including mitogens, neurotransmitters, ATP, hormones, 
growth factors, and physical stimuli such as pressure and turbulent flow.  
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Figure 1: The Metabolism of Arachidonic Acid.  
The metabolism of arachidonic acid by the two isoforms of the cyclooxygenase enzyme, 
and the specific synthases that produce the various prostanoid products.  
 
The rate-limiting step in the metabolism of arachidonic acid involves the enzyme 
cyclooxygenase, which is responsible for the sequential biosynthesis of the prostanoid 
endoperoxide precursors: beginning with the conversion of arachidonic acid to 
prostaglandin G2 (PGG2) and then the conversion of PGG2 to prostaglandin H2 (PGH2) 
(Figure 1). PGH2 is further metabolized into prostaglandin I2, F2α, D2, E2 and 
thromboxane A2 (TxA2) by specific synthase enzymes that are present within the nuclear 
and plasma membranes. The prostanoids produced have varying physiological effects 
and each tissue or organ has a specific profile of prostanoid production, dependent upon 
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the relative levels of the specific synthase enzymes. Vane discovered that inhibition of 
the COX enzyme by aspirin caused a decrease in the various prostanoids produced in the 
body responsible for pain, inflammation, fever, and platelet aggregation.   
 
2.2 Synthesis, Metabolism and Function of Prostanoids 
The various prostanoids synthesized from arachidonic acid metabolism act at 
specific receptors throughout the body to exert their effects via specific intracellular 
pathways. Prostacyclin (PGI2), is synthesized from PGH2 by prostacyclin synthase, 
which belongs to the cytochrome P450 superfamily of enzymes and is highly expressed 
in endothelial cells, vascular smooth muscle cells (VSMC), neurons, and intestinal 
epithelial cells (65). PGI2 is a potent vasodilator and inhibitor of platelet aggregation, as 
the preferential ligand to act at a G-protein coupled receptor, the IP receptor, found on 
cell surfaces throughout the body, including VSM and endothelium. Binding of the IP 
receptor activates adenylyl cyclase, and thereby the accumulation of cAMP, which 
activates an intracellular effector protein kinase A (PKA) to phosphorylate downstream 
targets (19, 21).  
PGF2α production is mediated by PGFα synthase and the PGF2α ligand binds the 
FP receptor, a G-protein coupled receptor, which increases intracellular calcium 
concentration. FP activation by PGF2α occurs during parturition in the female 
reproductive system, in the kidney to cause natriuresis and diuresis, and in the eye to 
regulate intraocular pressure (67).   
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The most abundant prostanoid produced in the body, PGE2, is involved in several 
physiological pathways, including gastric secretion and motility, inflammation, and body 
temperature, and also plays a role in the regulation of the kidney and blood pressure. The 
production of PGE2 is mediated by three known PGE synthases: one cystolic, cPGES, 
and two membrane bound, mPGES-1, and mPGES-2. PGE2 activates various receptor 
subtypes (EP1, EP2, EP3, EP4, and multiple splice variants of these) that are coupled to 
diverse signaling pathways which induce specific physiological effects (56).  
Another prostanoid, PGD2, is synthesized from PGH2 by PGD synthase and acts 
at two separate PGD receptors (DP1 and DP2) in the central nervous system, endothelial 
cells of the vascular wall, and commonly in immune cells. PGD2 is the common 
prostaglandin involved in allergic reactions, and in regulation of sleep. When activated, 
the DP1 and DP2 receptors elevate intracellular calcium levels via two separate 
pathways.  
Metabolism of PGH2 into TxA2 by thromboxane A2 synthase (TxS) was first 
discovered as the major product of platelets, and later found to be a minor product of 
endothelial cells and VSM. TxA2 has a very short half-life, during which it binds to a G-
protein receptor known as the T-prostanoid (TP). Although TxA2 is the preferential 
ligand at the TP receptor, PGH2 and other PGI2 can also bind TP (20). Upon activation 
of the TP receptor, intracellular activation of phosopholipase C (PLC) occurs to 
stimulate two secondary messengers, IP3 and DAG that activate protein kinase C (PKC). 
PKC serves to activate several downstream targets, which cause vasoconstriction in the 
vasculature and cause stimulation of platelet aggregation (23, 26, 58). Activation of the 
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TP receptor can also lead to impaired endothelial nitric oxide-mediated vasorelaxation, 
further leading to increases vascular tone and constriction (45).  
Numerous studies in both human and rodents have shown that the gastric mucosa 
produces PGE2, PGI2, PGD2, and PGF2α, with the latter two in minimal amounts (39, 
57). Prostaglandins PGI2 and PGE2 are secreted by the mucosa and act to protect the 
lining of the stomach by stimulating mucus and bicarbonate secretion, regulating acid 
secretion and stimulating vasodilation to increase blood flow (28). Loss of prostaglandin 
synthesis in the stomach can lead to disruption of the homeostatic pH gradient that 
protects the gastric mucosal lining, causing ulceration. Additionally, loss of 
prostaglandins during ischemia-reperfusion injury of the stomach disrupts the 
maintenance of blood flow, causing further injury (75).  NSAIDs, particularly aspirin 
and indomethacin, are documented to cause the most gastric damage due to their 
inhibitory effect on prostaglandin synthesis by COX-1 (60). 
 
2.3 Cyclooxygenase-2 Discovery 
Following Vane’s discovery of the mechanism of action of aspirin, research 
focused on the effects of NSAIDs on the production of prostanoids. A breakthrough in 
prostanoid research came in the early 1990’s when a mitogen-inducible form of the COX 
enzyme, now known as COX-2, was identified (79). Numerous follow-up studies 
confirmed that COX-2 expression was commonly induced at the site of inflammation 
and in the presence of growth factors, bacterial endotoxins, cytokines, and by hormonal 
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regulators such as estradiol (36, 55, 66).  More recently, the expression of COX-2 
mRNA and protein was found to be constitutive in the systemic vascular wall (43). 
The discovery of the COX-2 isoform opened the doors to numerous hypotheses 
addressing the production of the various prostanoids. Because COX-2 was initially 
found mainly in various forms of inflammation, Needleman and colleagues hypothesized 
that COX-2 expression was an inducible isoform of the COX enzyme upregulated during 
inflammation to produce pro-inflammatory prostanoids such as PGE2 and PGI2, while 
the expression of COX-1 was constitutive, and played a role in normal cell physiology, 
and functioned to produce anti-inflammatory prostanoids. In support of this hypothesis, a 
study in 1993 of the basal release of eicosanoids from murine macrophages showed that 
only low levels of COX-1 were expressed in untreated cells, but COX-2 was also present 
in cells treated with endotoxin (50).  Many studies confirming similar results led to the 
widespread belief that COX-1 was constitutively expressed and produced 
“housekeeping” prostanoids, while the induction of COX-2 expression during 
inflammation produced unfavorable prostanoids such as PGI2 and PGE2, which are 
known to potentiate inflammation.  
The importance of the constitutively produced prostanoids is evident in 
retrospective studies of NSAID use. Meta-analyses of case-control studies show that the 
use of non-aspirin NSAIDs increases the risk of upper gastrointestinal tract 
bleeding/perforation four-fold compared with non-users (33). In an overview of random 
control trials examining the GI toxicity of aspirin, the odds ratio for gastric ulcers was 
4.7 and odds ratio for all GI bleeding was 2.8 (61). It is important to note that aspirin, 
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which acts by acetylating a serine residue on the COX enzyme, is a selective, 
irreversible inhibitor of COX-1, with an IC50 of 0.3μg/ml for COX-1 versus 50μg/ml for 
COX-2 (50). These studies provide evidence that prostaglandin production via COX-1 is 
necessary for GI maintenance. Based on the evidence that COX-1 inhibition caused a 
disturbance in GI prostanoid synthesis, researchers believed it would be favorable to be 
able to block COX-2 expression selectively, while preserving the function of COX-1-
derived prostanoids in order to avoid the deleterious effects associated with the existing 
NSAIDs on the market.   
 
2.4 COX-2 Selective NSAIDs 
After the identification and purification of COX-2, pharmaceutical companies 
focused on the development of more selective drugs targeting the COX-2 enzyme to 
avoid potential GI side-effects associated with COX-1 inhibition and to target the 
inhibition of pro-inflammatory prostaglandins. The first COX-2 selective NSAID 
(known commonly as coxibs) was originally marketed in 1999, when G.D. Searle and 
Pfizer (now Pfizer Inc.) introduced celecoxib (Celebrex®). Merck followed shortly 
thereafter with the COX-2 selective drug, rofecoxib (Vioxx®). Both celecoxib and 
rofecoxib had instant success in the pharmaceutical market, with sales exceeding one 
billion dollars in the first 15 months of sales (59). It is important to note that coxibs are 
different compared to traditional NSAIDs in that coxibs are COX-1 sparing drugs. 
Coxibs highly inhibit COX-2 (standard inhibition is ~80%) without affecting COX-1 
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(less than ~10% inhibition), yet NSAIDs and coxibs are similar in that they both inhibit 
COX-2 significantly (76).  
Coxibs were praised as ‘wonder drugs’ after results from multiple studies, 
including the Vioxx Gastrointestinal Outcome Research (VIGOR) clinical trial, 
confirmed that significantly fewer patients treated with rofecoxib experienced 
gastrointestinal symptoms compared to naproxen (7). Additionally, a systematic review 
of randomized controlled trials has shown that COX-2 selective inhibitors produced 
significantly fewer gastroduodenal ulcers (RR 0.26; 95% CI 0.23, 0.30) and clinically 
important ulcer complications (RR 0.39; 95% CI 0.31, 0.50) than non-selective NSAIDs 
(63). The results seen in these trails were attributed to coxibs’ ability to spare COX-1. 
However, not long after the release of the first COX-2 selective NSAIDs, 
concerns were raised regarding adverse effects of the new drugs on the cardiovascular 
system. The VIGOR trial, which compared naproxen, a COX-1 inhibitor, with rofecoxib, 
a selective COX-2 inhibitor, had some surprising results in that the patients receiving 
rofecoxib had a fivefold increase in myocardial infarction in addition to the twofold 
reduction in severe gastrointestinal side effects (6). Due to these findings, the United 
States Food and Drug Administration (FDA) called for the removal of rofecoxib 
(Merck), in 2004, and valdecoxib (Pfizer), in 2005, from the market (32). However, the 
results of the VIGOR trial have been widely disputed based on multiple issues with the 
trial that were discussed or presented after the conclusion. Many disapproved of the 
conclusions drawn from the VIGOR trials based on the short duration of the trial, small 
sample size, and lack of suitable control. Indeed, there is evidence that naproxen can 
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provide sustained inhibition of platelet COX-1 when given at twice-daily doses, offering 
support to the view that the VIGOR results may have been biased (74). From these 
studies, the belief that selective inhibition of COX-2 causes deleterious cardiovascular 
side-effects was born. In order to understand why an increased risk of cardiovascular 
events would be caused by selective COX-2 inhibition, it is necessary to understand the 
origins and effects of prostanoids in the vascular system. 
 
2.5 Role of Prostanoids in the Vascular System 
Homeostasis within the vascular system relies on the balance of two functionally 
antagonistic prostanoids, TxA2 and PGI2.  In normal physiological conditions, PGI2, 
which acts as a vasodilator and inhibits platelet aggregation, is the major product of the 
vascular endothelium and vascular smooth muscle (VSM). TxA2 is produced in much 
smaller amounts by the endothelium, VSM, and platelets, and acts antagonistically to 
PGI2, causing vasoconstriction and platelet aggregation. Thus, vascular homeostasis and 
its key components (tone and hemostasis) depend upon the balance between PGI2 and 
TxA2. Because only one COX isoform was known for years, it was originally believed 
that TxA2 and PGI2 were both products of the same COX-1. After the discovery of 
COX-2, the prevailing view of the origins of TxA2 and PGI2 shifted.  
It was previously believed that COX-2 expression was induced during 
inflammatory states, but there is now clear evidence to show that COX-2 is 
constitutively expressed in tissues such as the aortic endothelium (35). Turnover of 
COX-2 mRNA is rapidly regulated by post-transcriptional mechanisms; therefore 
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immunohistochemistry of COX-2 enzyme levels is likely an inaccurate measurement of 
the actual amount present or active in tissues. In addition, COX-2 is more active at lower 
substrate and hydroperoxide concentrations, therefore it is likely that a large amount of 
PGI2 is synthesized by relatively small amounts of COX-2 in the vasculature (26). TxA2 
is historically a product of COX-1 in the platelets, but more recent studies suggest that 
the vascular endothelium synthesizes TxA2 through either COX-1 or COX-2. Due to 
differences in COX expression and regulation, it is difficult to identify the origin of 
vascular prostanoid synthesis by each COX isoform.  
PGI2 is commonly found at sites of inflammation, in addition to its role in many 
housekeeping functions including renal blood flow regulation and gastric acid secretion. 
It was historically believed that in endothelial cells, COX-1 was the source of PGI2. In 
1999, the first study was published showing the effects of a COX-2 selective inhibitor 
drug on vascular prostanoid levels. The results were puzzling, as they showed the use of 
celecoxib depressed urinary PGI-M levels. This was the first time that PGI2 was reported 
to be derived from COX-2 (47). Although these results were debated due to the unclear 
origin of urinary PGI-M metabolites, in 2007, the American Heart Association (AHA) 
published its acceptance of PGI2 as the main product of COX-2 in endothelial cells (3). 
However, contrary to these aforementioned data that COX-2 is the main source of PGI2, 
functional studies in humans have shown that PGI2 levels are abolished by low doses of 
a selective COX-1 inhibitor, aspirin (42). Indeed, as recent as 2012, studies have 
continued to reverse those early reports that PGI2 originates from COX-2 (37). Taken 
together, these studies provide strong evidence that both COX-1 and COX-2 are 
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involved in the biosynthesis of PGI2. It is now known that, due to differences in the 
regulation of expression, it is possible for both COX-1 and COX-2 to function 
independently within the same cell (10, 14, 18, 43, 49). 
TxA2 is produced in minor amounts, but nevertheless acts antagonistically to 
PGI2 to cause platelet aggregation and vasoconstriction. Upon platelet activation by 
thrombin, release of TxA2 serves to increase platelet coagulation and vascular tone. In 
studies using TP receptor deficient mice, increased bleeding time was observed as an 
abnormal vascular response due to delayed platelet aggregation (70).  Additional roles of 
TxA2 in the vascular system include neovascularization and atherogenesis. It has long 
been known that TxA2 synthesis is a product of COX-1 expression in the platelets; 
however, recent studies have shown that COX-2 expression in vascular smooth muscle 
(VSM) and endothelial cells can also produce TxA2 (4, 43, 59).  
 
2.6 The Imbalance Theory 
Although PGI2 is produced in much larger amounts than TxA2, the balance 
between these two mediators is very important to the maintenance of vascular health. 
The imbalance theory states that a negative shift in the balance between PGI2 and TxA2 
can lead to the pathogenesis of cardiovascular diseases such as coronary artery disease 
and stroke. A decrease in the major prostanoid released, PGI2, may cause a shift in the 
balance from dominance by the anti-aggregatory, vasodilatory PGI2 to the pro-
aggregatory, vasoconstrictor TxA2, increasing the deleterious influences of the latter. In 
theory, COX-1 synthesizes the majority of TxA2 while COX-2 produces antagonistically 
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functioning PGI2. The imbalance theory is commonly the scapegoat for an increased risk 
of thrombosis with coxib use, because of the belief that PGI2 is mainly derived from 
COX-2 activity. 
   The unexpected deleterious effects of coxibs on the cardiovascular system 
started an ongoing dilemma within the medical community. A highly desirable effect of 
coxibs was the reduced the risk of GI disturbances through the sparing of COX-1 
function. Conversely, an unforeseen drawback of selectively inhibiting COX-2 was the 
increased risk of harmful cardiovascular effects by altering the PGI2/TxA2 balance 
toward TxA2. Many have claimed these effects can be explained by the imbalance 
theory, resulting from the increase in TxA2 and the decrease in PGI2 levels. However, 
there are several studies which suggest that the imbalance theory is flawed on the basis 
that urinary PGI2 metabolite levels do not accurately reflect measurements of vascular 
PGI2 synthesis (24). Therefore, the studies that originally proposed that coxibs cause an 
increased risk of thrombosis due to a selective decrease in PGI2 without depressing TxA2 
levels are not valid. Although the imbalance theory may not accurately depict the 
underlying mechanisms, the fact that COX-2 selective drugs produce an increased risk of 
thrombotic events is indisputable. In light of this, other theories describing the possible 
mechanisms responsible for increased cardiovascular risk with the use of coxibs have 
arisen.  
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2.7 Thromboxane and Prostacyclin Pathway Interaction  
The actions of TxA2 and PGI2, and their respective receptors’ are known to 
interact through several mechanisms to alter the release and/or production of these 
mediators in the cardiovascular system. Activation of the TP receptor appears to 
mobilize calcium in endothelial cells and cause the release of the antagonistic mediator, 
PGI2 (34). PGI2 release modulates the effects of TxA2 in the vasculature, by limiting 
TxA2 production (80). Furthermore, PGI2 receptor (IP) activation reportedly depresses 
TxA2 response by down regulating expression of the TP receptor (29). These interactions 
may be due to heterodimerization of the TP and IP receptors that result in cross-talk 
between the two prostanoid receptors in endothelial cells (19). Another mechanism of 
cross-talk between TxA2 and PGI2 includes the independent promotion or repression, of 
prostanoid receptor expression due to the overlapping genetic response elements for the 
TP and IP receptors (29). It has been speculated that TxA2 depresses PGI2 synthesis 
through activation of the TP receptor and subsequent activation of intracellular protein 
kinase C (PKC), which causes nitrosylation of a tyrosine residue on the PGIS enzyme, 
reducing its activity and the synthesis of PGI2. If correct, this intriguing theory would be 
the first evidence that TxA2 negatively regulates PGI2 synthesis in the vascular wall.   
 
2.8 Sexual Dimorphism in Cardiovascular Function 
Sexual dimorphism is a factor that contributes to the incidence of cardiovascular 
disease, but that is often overlooked. Many epidemiological studies reveal that the 
incidence of cardiovascular disease is greater in men than in premenopausal women, 
  16 
suggesting that sex steroids, especially estrogen, may protect women from such 
pathophysiological states. Carotid atherosclerosis in postmenopausal women is notably 
more prevalent than in premenopausal women (54% vs 25%,  respectively) suggesting 
that changes that occur in female body during menopause may have deleterious effect on 
the cardiovascular system (69).  Additionally, postmenopausal women have an incidence 
of coronary heart disease (CHD) similar to that of men. These findings suggest that the 
presence of circulating ovarian steroid hormones exert a protective effect on the 
cardiovascular system. On the other hand, more recent epidemiological studies in 
women and experimental studies in animals reveal that CVD that are primarily vascular 
in origin occur more frequently in females and are exacerbated in the presence of 
estrogen (31, 43). 
 
2.9 Role of Estrogen in the Cardiovascular System 
Beginning in 1992, a series of studies were published which concluded that 
estrogen reduces the risk for CHD by a substantial amount, some claiming a 35% 
reduction, others 40% to 60% (30, 31). However, more recent clinical trials in 
conjunction with recent epidemiological studies challenge these earlier studies and 
suggest that estrogen is not protective against CHD. The Heart and Estrogen/Progestin 
Replacement Study (HERS) was the first randomized, double-blind, placebo-controlled 
study that evaluated postmenopausal women with established CHD treated with estrogen 
replacement therapy (ERT). The HERS study found no difference in cardiac outcome 
between estrogen-treated and placebo-treated women after 4.1 and 6.8 years follow up, 
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therefore repealing the initial proposal that estrogen plays a protective  role in women 
(77, 78). The HERS study was widely quoted, and somewhat misinterpreted, in the years 
following. In 2001, at the recommendation of the Journal of the American Heart 
Association, the American Heart Association (AHA) advised against the prescription of 
ERT in women with preexisting cardiovascular disease. However, these warnings were 
taken out of context and caused confusion in the medical community leading many to 
believe that all women on ERT had an increased risk for CVD (48). One problem with 
the AHA making recommendations from the conclusions of the HERS Study, is that that 
the sample of women included only represented a small population of postmenopausal 
women with established CHD. The current dogma is that in postmenopausal women, the 
loss of female sex steroids exerts a deleterious effect on the cardiovascular system, while 
the existence of sex steroids in premenopausal women has a protective effect.  
Estrogen may exert either beneficial or detrimental effects on the vasculature 
depending on the estrogen receptors (ER) present. There are both membrane-bound and 
cytosolic target receptors in the endothelium cells (45). Both cell types contain α and β 
receptors, the two classical types of ER.  Activation of an ER stimulates different 
signaling pathways and changes in expression of target genes, leading to various effects, 
such as protein synthesis and cell proliferation (16). In human studies, estrogen directly 
increases the expression of the PGI2 receptor (IP) within the vasculature through an ERα 
transcriptional mechanism (72). Recent evaluation of the role of ERα and ERβ on the 
balance of PGI2/TxA2 in cultured human umbilical vein endothelial cells (HUVEC) 
revealed multiple mechanisms by which estrogen exerts cardioprotective effects. After 
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exposure to estradiol, production of PGI2 was increased in a dose-dependent manner, 
while expression of both COX-1 and PGIS genes and their proteins were increased by 
20% and 50%, respectively. These effects were dependent upon the activation of ERα by 
17β-estradiol (E2). In this study, TxA2 was unaltered by exposure to E2.  In similar 
studies, PGI2 production was also increased in response to an increase in E2 and COX-1 
(1). These data reveal that through ERα, estradiol enhances PGI2 production by 
increasing both COX-1 and PGIS expression, shifting prostanoid balance in favor of the 
beneficial PGI2 (68).  Although ERα is known to have protective effects in the 
vasculature, ERβ has been rarely documented to have an effect on prostanoid 
production. 
 In studies investigating the effects of E2 on cultured endothelial cells, E2-induced 
activation of protein kinase C (PKC) resulted in increased expression of COX-2 (30). 
Similarly, studies in intact arterial vessels revealed that COX-2 mRNA and protein 
expression are attenuated in the absence of estrogen in ovariectomized (OvX) female 
rats and are enhanced in intact female (Int) and OvX + E2-replaced rats (1, 43). 
Additionally, it was reported that serum estradiol levels coincide with COX-2 expression 
throughout the estrus cycle, with levels of estradiol and COX-2 expression peaking 
during proestrus and both plummeting during diestrus (54). Together, the results from 
these studies suggest that estrogen exerts its protective effect on the vasculature by 
activating ERα, thereby increasing gene expression of IP, PGIS, and both COX-1 and 
COX-2 causing an increase in PGI2 production.  
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 In contrast, recent studies have revealed that estrogen can also potentiate 
thromboxane pathway expression in endothelial cells and VSM, enhancing constrictor 
function. Estrogen potentiated the release of and the reactivity to TxA2 by upregulating 
mRNA and protein expression of COX-2, TxS, and TP in the female rat aorta. These 
results were attenuated in ovariectomized female (OvX-F) rats and restored in OvX-ERT 
rats (43).  These results were one of the few recent studies to reveal that estrogen can 
exert deleterious effects, despite the largely accepted dogma that estrogen plays a 
beneficial role in cardiovascular function.  
 Our lab has previously reported that a more complex relationship exists between 
the TxA2 and PGI2 biosynthesis pathways, and that the presence of TxA2 may negatively 
regulate PGI2 production. The inhibition of the TxA2 synthesis pathway using 
Dazoxiben (Daz, TxS inhibitor) enhanced production of PGI2. This evidence suggests 
that TxA2 may attenuate PGI2 synthase (PGIS). A possible mechanism of action for this 
may be protein kinase C (PKC) nitration of a tyrosine residue on PGIS (12). 
 
2.10 Statement of Objectives and Investigation Rationale 
2.10.1 Objectives  
 The prostanoid biosynthesis profiles of the major COX isozymes in the vascular 
wall remain uncertain. PGI2 (the main prostanoid produced by the endothelium and 
VSM) was initially believed to be the main product of the COX-2 isoform; however, it 
was also synthesized also by COX-1 in more recent studies (37). Similarly, TxA2 was 
initially believed to be produced mainly by COX-1 in platelets; however, more recent 
  20 
studies revealed that estrogen potentiates COX-2 expression in the vasculature and may 
be responsible for increased TxA2 production in the female rat aorta (43). If the COX 
isoforms present in the endothelium and VSM determine the production of PGI2 and 
TxA2, then inhibition of a specific COX enzyme (COX-1 or COX-2) should yield a 
specific ratio of PGI2/TxA2. The ratio of PGI2/TxA2 production in the vascular wall 
plays an important role in the vascular homeostasis; therefore, it is important to 
understand the relative roles of COX-1 and COX-2 in this balance. The experiments in 
this thesis were designed to clarify the roles of COX-1 vs. COX-2 in the production of 
PGI2 and TxA2 and the vascular wall. 
 
 
2.10.2 Rationale 
 The existing “imbalance theory” dominates the view regarding the roles of 
vasodilator prostacyclin (PGI2) versus vasoconstrictor thromboxane (TxA2) in vascular 
homeostasis and the pathogenesis of vascular dysfunction and thrombosis. In theory, 
vascular tone and hemostasis are dependent upon a greater ratio of PGI2-derived via 
COX-2 than platelet-derived TxA2 via COX-1(24). Thus, a selective COX-2 inhibitor 
would alter this balance in favor of TxA2 synthesis, producing vasoconstriction, platelet 
aggregation, and thrombosis. Concern over the cardiovascular risks associated with the 
vascular effect of selective COX-2 inhibitors forced the Food and Drug Administration 
(FDA) to remove multiple COX-2 selective NSAIDs from the market, citing the 
imbalance theory as the likely cause for such risks (41). However, recent reports suggest 
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that the assumptions upon which the imbalance theory is based are incorrect, and 
therefore the validity of the theory is now in question (22, 24).  
  Based on the measurements of 2,3-dinor-6-keto PGF1α ((PGI-M), the major 
urinary metabolite of PGI2), it was proposed that endothelial COX-2 was the primary 
mediator of PGI2 formation; however, this theory was challenged recently on the basis 
that the use of urinary metabolites of PGI2 as a means of measuring prostacyclin from 
vascular tissues is inaccurate. Because PGI2 acts locally at its site of production, and that 
other, non-endothelial sources of PGI2 exist throughout the body that could contribute to 
levels measured in the urine, urinary metabolites provide an inaccurate measurement of 
vascular production of PGI2 (22, 53). Several methods of analysis using direct 
measurement from the vasculature suggests that in the normal state, endothelial cells in 
human coronary arteries, coronary arterioles, carotid arteries, aorta, and other vascular 
sources express high levels of the COX-1 enzyme, but not the COX-2 enzyme [1]. In 
human studies using low doses of aspirin, a selective COX-1 inhibitor (35-75mg/day), 
vascular levels of PGI2 and TxA2 were both abolished. These studies show that, unlike 
previous reports, the COX-1 enzyme generates PGI2 in the vasculature. Therefore, 
selective inhibition of COX-2 may not affect the local levels of PGI2 in the vasculature, 
and should not increase the likelihood of thrombotic events (71). Taken together, these 
findings suggest that the assumption that COX-2 selective inhibitors tip the scales in 
favor of prothrombotic TxA2 formation is flawed on the basis that significant amounts of 
PGI2 appear to be derived from COX-1 in the endothelium.  
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 The importance of sex differences in vascular physiology is often overlooked, 
especially as it pertains to the balance of prostanoid activity. The incidence of 
cardiovascular disease is higher in men than women, as demonstrated by a variety of 
earlier epidemiological studies. Several recent studies have shown that estradiol (E2), the 
most potent estrogen in humans, exerts its effects on prostanoid biosynthesis by 
upregulation of COX-2 in the endothelium and vascular smooth muscle (43). Therefore, 
estrogen may play a protective role in the vasculature in females as it potentiates PGI2 
release from the endothelium.  Our lab previously reported that TxA2 exerts an 
inhibitory effect on PGI2 production, an effect found to be greater in male than female; 
however, the mechanism of action is unknown. This research was designed to determine 
the role of PGI2/TxA2 cross-talk in prostanoid balance in the vascular wall. 
 Many of the studies that have examined the roles of COX-1 and COX-2 in the 
vasculature were performed solely in males. The roles of sex and the sex hormones in 
the production of prostanoid synthesis have been commonly disregarded in vascular 
physiology and pharmacology. Estrogen is now known to increase the expression of both 
COX-1 and COX-2 in the vasculature (43, 52). Therefore, the effects of sex and the sex 
steroids in balancing prostanoid synthesis may play a larger role in the cardiovascular 
system than previously believed. The proposed research was expected elucidate the role 
of estrogen in regulating the balance between COX-1 and COX-2 and the production of 
TxA2 and PGI2 in the vascular wall. Thus, the overall hypothesis to be tested is as 
follows (Figure 2): 
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Figure 2: Hypothesis. 
 
2.10.3 Specific Aims 
 The specific aims of this project are to determine: 
1) the relative roles of COX-1 vs. COX-2 in the production of TxA2 and PGI2 by 
the female vs. male rat aorta 
2) the role of estrogen in the production of vascular prostanoids PGI2 and TxA2 in 
 the female rat aorta 
3)  cross-talk between PGI2 and TxA2 pathways, specifically the mechanism by 
which TxA2 inhibits PGI2 synthesis in the vascular wall 
Inhibition of COX-1 will reduce TxA2 to a greater extent than PGI2 production, whereas 
COX-2 inhibition will reduce PGI2 production to a greater extent than TxA2 production 
in the rat aorta. Furthermore, estrogen replacement will enhance synthesis of COX-2 
derived prostanoids, but have no effect on COX-1 prostanoid products. 
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CHAPTER III  
EXPERIMENTAL DESIGN AND METHODS 
 
3.1. Project I 
3.1.1 Experimental Animals and Maintenance 
 Age-matched (14-16 week old) male and female Sprague-Dawley rats (Harlan, 
Houston, TX) were used in all experiments. The rats were housed in the Laboratory 
Animal Resources and Research facility (LARR) with controlled temperature (22–
24°C), relative humidity (∼50%), and 12-h:12-h light-dark cycle. The rats were 
provided with a 16% protein phytoestrogen-free rat chow and tap water ad libitum. All 
experiments were reviewed and approved by the Texas A&M University Institutional 
Animal Care and Use Committee (IACUC). The rats were randomly divided into four 
treatment groups: Males (M), intact females (Int-F), ovariectomized females (OVX-F), 
and OVX-estrogen-replaced (OvX-ER-F) females.  
 
3.1.2 Ovariectomy and Estrogen Replacement Therapy 
 Bilateral ovariectomy surgery (OvX Sx) was performed on 14-week-old females 
using standard methods. Half of the OvX rats received estrogen replacement therapy 
using 17β-estradiol (3 x 0.05 mg/60-day release pellets, Innovative Research; Sarasota, 
FL). Previous studies have shown that this dose produces physiological plasma levels of 
17β-estradiol that are similar to Int-F rats (64).  
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3.1.3 Animal Sacrifice, Tissue Preparation, and Experimental Set Up 
 Rats were sacrificed 14-16 days post-OvX or post OvX+ER by rapid 
decapitation, in accordance with American Veterinary Medical Association and Texas 
A&M University IACUC guidelines. At the time of decapitation, trunk blood was 
collected for RIA of plasma 17β-estradiol. The thoracic aorta was removed gently 
without stretching and cleaned of all adipose and connective tissue, then sectioned into 
aortic rings 3mm in length. Krebs-Henseleit-Bicarbonate (KHB) buffer was prepared 
daily and kept chilled (4°C), gassed (95% O2-5% CO2), and composed of (in mM) 118.0 
NaCl, 25.0 NaHCO3, 10.0 glucose, 4.74 KCl, 2.5 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4 
(pH 7.40; osmolality, 292 ± 1 mosmol/kgH2O).  
 The aortic rings were kept in KHB at 4°C throughout dissection and during a 45-
minute stabilization period. Two aortic rings each were placed in a 12 x 75 µm plastic 
culture tube containing 2 mL pre-incubation KHB, either vehicle (basal), SC-560 (a 
selective COX-1 inhibitor, 10-7 M), or NS-398 (a selective COX-2 inhibitor, 10-5) for a 
pre-incubation period of 30-minutes to gradually warm the rings to 37°C. The 
concentration of each inhibitor used was formulated to be ten times the IC50 provided 
from Caymen Chemicals (IC50 = SC-560: 9nM, NS-398:0.15µM). The pre-incubation 
buffer was removed and replaced with 1mL incubation buffer, either KHB vehicle 
(basal), vasopressin (VP; 10-6 M), VP+SC-560 (10-7 M), or VP+NS-398 (10-5 M) and 
incubated at 37°C and gassed continuously for 45 minutes. The treatment buffer was 
removed and stored at -80°C until RIA of TxB2 and 6-keto-PGF1α was performed. 
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Prostanoid release was normalized by dry tissue weight of the aortic rings and expressed 
as pg/mg dry tissue wt/45 minutes.   
3.1.4 Plasma Estrogen Measurement 
 Following decapitation, trunk blood was collected into 13 x 100-mm glass 
culture tubes coated with 150 U of EDTA, centrifuged (10,000 g for 5 min), and the 
resultant plasma separated and stored at -80°C until RIA of 17β-estradiol was 
performed. The estradiol concentrations were measured in duplicate using a double-
antibody RIA (Diagnostic Products; Los Angeles, CA) and validated for measurements 
of rat plasma (43). Plasma 17β–estradiol concentrations were expressed as pg/mL 
plasma. 
 
3.1.5 Vaginal Smears 
 Vaginal smears were performed on Int-F each day for two weeks leading up to 
the day of sacrifice in order to determine phase of the estrous cycle. The smears were 
dried and stained with crystal violet then analyzed under a microscope for the presence 
of phase-specific cell types. The phase of the estrus cycle was determined based on the 
histological profile observed. The proestrus stage was identified by a predominance of 
nucleated epithelial cells; the estrus stage was identified by anucleated cornified cells; 
the diestrus stage was identified by a mix of all cell types: nucleated epithelial cells, 
anucleated cornified cells, and a small presence of leukocytes; the metestrus stage was 
identified by the overwhelming presence of rounded leukocytes (46). 
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3.1.6 Radioimmunoassay Measurement of Thromboxane A2 and Prostacyclin 
  Specific RIAs for 6-keto-PGF1α (a stable metabolite of PGI2) and TxB2 (a stable 
metabolite of TxA2) were used to measure prostanoid concentrations in the tissue 
incubation media. 100μL of sample was incubated with [3H] 6-keto-PGF1α and with 
antiserum overnight at 4°C. The charcoal-dextran method was used to separate bound 
and free fractions of PGI2. 100μL of sample was also used for RIA of TxB2 using a 
commercial kit from Caymen Chemicals. Bound radioactivity from each RIA was 
counted by liquid scintillation spectroscopy. The limit of detection of the PGI2 RIA was 
3.90 pg/mL and 1.95 pg/mL for TxB2. 
  
3.1.7 Experimental Design 
 The experiments were designed to determine: 1) The relative roles of COX-1 
versus COX-2 in the production of PGI2 vs. TxA2 by the vascular wall, and: 2) The 
effects of estrogen on the production of COX-1-derived vs. COX-2-derived prostanoids 
and 3) The cross-talk effects of TxA2 on PGI2 release.  
 
3.1.8 Data Analysis 
 The data were expressed as the mean ± standard error with “n” indicating the 
number of animals in each experimental group. A two-way analysis of variance (sex vs. 
treatment) with repeated measures was used to detect significant differences among the 
experimental groups, Int-F (intact female), OvX-F (ovariectomized female), OvX-ER-F 
(ovariectomized, estrogen-replaced female), and M (male), and the treatments, basal, 
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VP, VP+SC-560, VP+NS-389, followed by a post hoc Tukey test to identify differences 
among the means of the experimental groups. The difference between COX-1 and COX-
2 inhibition (∆ VP by SC-560 and NS-398) was evaluated by a two-way analysis of 
variance (sex vs. treatment) with repeated measures followed by a post hoc Tukey test. 
A P value of ≤0.05 was considered statistically significant. 
 
3.2 Project II  
3.2.1 Experimental Animals and Maintenance 
 14-16 week old male Sprague-Dawley rats (Harlan, Houston, TX) were used in 
all experiments. The rats were housed in the Laboratory Animal Resources and Research 
facility (LARR) with controlled temperature (22–24°C), relative humidity (∼50%), and 
12-h:12-h light-dark cycle. The rats were provided 16% protein phytoestrogen-free rat 
chow and tap water ad libitum. All experiments were reviewed and approved by the 
Texas A&M University Institutional Animal Care and Use Committee (IACUC).  
 
3.2.2 Animal Sacrifice and Experimental Set Up 
 Rats were sacrificed by rapid decapitation, in accordance with American 
Veterinary Medical Association and Texas A&M University IACUC guidelines. The 
thoracic aorta was removed gently, without stretching, and placed in chilled (4°C), 
gassed (95% O2-5% CO2) Krebs-Henseleit-bicarbonate buffer (KHB). The aorta was 
cleaned of all adipose and connective tissue, and then sectioned into rings measuring 
3mm in length. KHB buffer was prepared daily and composed of (in mM): 118.0 NaCl, 
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25.0 NaHCO3, 10.0 glucose, 4.74 KCl, 2.5 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4 (pH 
7.40; osmolality, 292 ± 1 mosmol/kgH2O).  
 The aortic rings were kept in KHB at 4°C throughout dissection and during a 45-
minute stabilization period. Two aortic rings were placed in each 12 x 75 plastic culture 
tube containing 2 mL pre-incubation KHB (either vehicle, Calphostin C (protein kinase 
C inhibitor; 10-6 M), Ridogrel (TxS inhibitor/TP receptor antagonist; 10μM), Furegrelate 
(TxS inhibitor; 50 μM) or Dazoxiben (TxS inhibitor; (50μM)). The rings were gradually 
warmed to 37°C during a 30-minute pre-incubation period and gassed constantly with 
95% O2-5% CO2. The pre-incubation buffer was removed and replaced with 1mL 
incubation buffer, (either vehicle vasopressin (VP; 10-6 M), or a combination of VP (10-
6M) + Calphostin C (10-6 M), VP + Ridogrel (10μM), or VP + Furegrelate (50μM), or 
VP + Dazoxiben (50μM)), and incubated at 37°C and gassed continuously for 45 
minutes. The treatment buffer was removed and stored at -80°C until RIA of TxB2 and 
6-keto-PGF1α was performed. Prostanoid release was normalized by dry tissue weight of 
the aortic rings and expressed as pg/mg dry tissue wt/45 minutes.   
 
3.2.3 Radioimmunoassay Measurement of Thromboxane A2 and Prostacyclin 
  Specific RIAs for 6-keto-PGF1α (a stable metabolite of PGI2) and TxB2 (a stable 
metabolite of TxA2) were used to measure the concentration in the samples collected 
from experimentation. 100μL of sample was incubated with [3H] 6-keto-PGF1α and with 
antiserum overnight at 4°C. The charcoal-dextran method was used to separate bound 
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and free fractions. Bound radioactivity was counted by liquid scintillation spectroscopy. 
The limit of detection of the RIA is 3.90 pg/mL for PGI2 and 1.95 pg/mL for TxB2. 
 
3.2.4 Experimental Design 
 The experiments were designed to determine the mechanism by which TxA2 
inhibits PGI2 synthesis in the vascular wall. We hypothesized that inhibition of PKC 
with Calphostin C would increase PGI2 production similarly to Dazoxiben and Ridogrel,  
TxS synthase inhibitor and combined TxS inhibitor and TP receptor antagonist., 
respectively. Furegrelate, a TP receptor antagonist should produce similar results to 
Calphostin C and Ridogrel, but should not increase PGI2 production as dramatically. 
  
3.2.5 Data Analysis 
 The data were expressed as the mean ± standard error with “n” indicating the 
number of animals in each experimental group. A one-way analysis of variance was used 
to detect significant differences among the treatments, VP, VP+Calphostin, 
VP+Furegrelate, VP+Ridogrel, VP+Dazoxiben followed by a post hoc Tukey test to 
identify differences among the means of the experimental groups. A P value of ≤0.05 
was considered statistically significant. 
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CHAPTER IV  
RESULTS 
 
4.1 Plasma Estrogen Concentrations 
 Plasma 17β–estradiol concentration was averaged 6.0 ± 2.1 pg/ml in Int-F rats 
and 24.5 ± 5.9 pg/ml in OvX-ER-F rats. OvX reduced plasma estradiol levels to 0.5 ± 
0.14 pg/mg, similar to levels found in M (0.59 ± 0.11 pg/ml). 17β–estradiol 
concentrations were significantly higher in Int-F and OvX-ER-F than in OvX-F or M 
rats (P=0.01, P=0.03). OvX-ER-F rats had significantly higher 17β–estradiol 
concentrations compared to Int-F (P=0.01). There were no significant differences in 
17β–estradiol concentrations between OvX-F and M rats (P≥0.05) (Table 1). 
 
Treatment Group Plasma 17-β-estradiol 
(pg/ml) 
Int-F 6.0 ± 2.1a 
OvX-ER-F 24.5 ± 5.9b 
OvX-F 0.50 ± 0.14c 
M 0.59 ± 0.11c 
Table 1: Plasma 17β–estradiol Levels. 
The average plasma 17β–estradiol levels from each group. Data are reported as the 
means ± SE of plasma estrogen levels in pg/ml.  
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4.2 Effects of COX-1 versus COX-2 Inhibition on PGI2 Release 
4.2.1 Prostaglandin I2  
4.2.1.1 Basal and VP-Stimulated PGI2 Release 
 Basal release of PGI2 from aortic rings was similar in all groups (Int-F (3,663 ± 
530 pg/mg ring wt/45 min); OvX-F (2,726 ± 436 pg/mg); OvX-ER-F (4,312 ± 341 
pg/mg); M (2,967 ± 850 pg/mg)) (P≥0.05) (Fig. 2).      
           
 
Figure 3: Basal Release of PGI2. 
Basal release of PGI2 (measured as the stable metabolite 6-keto-PGF1α) from rat thoracic 
aortic rings. Bars are means ± S.E. Int-F, intact female; OvX-F, ovariectomized-females; 
OvX-ER-F, ovariectomized-estrogen replaced female; M, male rats. PGI2 release did not 
differ significantly among any of the experimental groups (P≥0.05). 
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 In response to VP (10-6M), PGI2 release markedly increased in Int-F (15,352 ± 
2,209 pg/mg) and OvX-ER-F (13,053 ± 3,086 pg/mg). This was markedly greater than in 
OvX-F (4,785 ± 773 pg/mg) or M (4,528 ± 745 pg/mg). Stimulation with VP produced 
was only significantly increased from basal in Int-F and OvX-ER-F (.001≤P≤0.05) 
(Figure 3: Basal release of PGI2). VP stimulated 6-keto-PGF2 419% above basal in Int-F 
and 303% in OvX-ER-F, whereas stimulation in OvX-F (176%) and M (159%) was 
increased markedly less (Figure 4, Table 2).   
 
 
Group                            PGI2 (pg/mg ring wt./45 min) 
                            Basal                        VP (10-6 M) 
 
Int-F (n=7) 
  
3,663 ± 530a 
 
15,352 ± 2,209b 
OvX-F (n=8)  2,726 ± 436a 4,785 ± 773a 
OvX-ER-F (n=7)  4,312 ± 341a 13,053 ± 3,086b 
Male (n=6)  2,844  ± 776a 4,528 ± 745a 
Table 2: Basal and VP-Stimulated Release of PGI2. 
Basal and VP-stimulated release of PGI2 (measured as 6-keto-PGF1α) in each group (n, 
number of animals per group).  
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Figure 4: Basal and VP-stimulated PGI2 Release.  
Basal and Vasopressin-stimulated release of PGI2 (measured as the stable metabolite 6-
keto-PGF1α) from thoracic aortic rings of Int-F, OvX-F, OvX-ER-F, and M rats. Bars are 
means ± S.E. Stimulation with VP caused a significant increase in release of PGI2 in Int-
F and OvX-ER-F (.001≤P≤0.05). VP stimulated PGI2 release was significantly greater in 
Int-F and OvX-ER-F than in OvX-F and M (.001≤P≤0.05).     
           
           
        
4.2.1.2 Effects of COX-1 Inhibition on VP-Stimulated PGI2 Release 
 Aortic rings from each group were pre-treated with the COX-1 inhibitor (SC-560; 
10-7M) and the effects of VP (10-6M) on PGI2 release was assessed. SC-560 reduced the 
maximal response to VP by 71% in Int-F (15,352 ± 2,209 to 4,421 ± 809 pg/mg), 74% in 
OvX-F (4,785 ± 773 to 1,264 ± 369 pg/mg), 62% in OvX-ER-F (13,053 ± 3,086 to 4,916 
± 923 pg/mg), and 61% in M (4,528 ± 745 to 1,768 ± 507 pg/mg). SC-560 significantly 
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decreased PGI2 in Int-F and OvX-ER-F to near or below basal concentrations (Figure 5). 
             
4.2.1.3 Effects of COX-2 Inhibition on VP-Stimulated PGI2 Release 
 Aortic rings from each group were pre-treated with the COX-2 inhibitor NS-398 
(10-5M) and the effects of VP (10-6M) on PGI2 release was assessed. NS-398 
significantly reduced the maximal response to VP by 83% in Int-F (15,352 ± 2,209 to 
2,498 ± 790 pg/mg), and 83% in OvX-ER-F (13,053 ± 3,086 to 2,282 ± 266 pg/mg), 
whereas the maximal response was decreased by 65% in OvX-F (4,785 ± 773 to 1,672 ± 
364 pg/mg) and 48% in M (4,528 ± 745 to 2,335 ± 713 pg/mg) (Fig.5). NS-398 
abolished the response to VP, and reduced PGI2 release to nearly 50% of basal 
concentrations in Int-F (basal=3,663 vs. NS-398=2,498 pg/mg) and OvX-ER-F 
(basal=4,312 vs. NS-398=2,282 pg/mg) (Fig. 4).  
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Figure 5: Effects of COX-1 and COX-2 Inhibition on VP-Stimulated PGI2 Release. 
Release of PGI2 (measured as the stable metabolite 6-keto-PGF1α) in response to VP-
stimulation (10-6M) versus COX-1 inhibition with SC-560 (10-7M) + VP-stimulation (10-
6M), or COX-2 inhibition with NS-398 (10-5M) + VP-stimulation (10-6M) from aorta in 
rats. Bars are means ± S.E. Both SC-560 and NS-398 significantly inhibited VP-
stimulated PGI2 release (.001≤P≤0.05). Inhibition by SC-560 and NS-398 did not 
significantly differ in OvX-F and M (P≥0.05).  
   
 
4.3 Effects of COX-1 versus COX-2 Inhibition on PGI2 Release 
 The effects of specific COX-1 and COX-2 inhibitors, SC-560 and NS-398, 
respectively, on PGI2 release, were investigated in the aorta of M and F rats. Release of 
PGI2 was similar in the presence of SC-560 in all groups (P<0.05). Likewise, release of 
PGI2 was similar in the presence of NS-398 in all groups. Inhibition of PGI2 release by 
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SC-560 and NS-398 did not differ in OvX-F (74% and 65%) or M (61% and 48%) rat 
aorta. (Table 3, Figure 4).  
 
 
Group 
(n≥6) 
High VP (10-6M) 
(pg/mg ring wt/45 min) 
SC-560 (10-7M) 
(pg/mg ring wt/45 min) 
NS-398 (10-5M) 
(pg/mg ring wt/45 min) 
Int-F 15,352 ± 2,209a  4,421 ± 809b  2,498 ± 790b 
OvX-F 4,785 ± 773b 1,264 ± 369b 1,672 ± 364b 
OvX-ER-F 
M 
13,053 ± 3,086a 
4,528 ± 745b 
4,916 ± 923b 
1,768 ± 507b 
2,282 ± 266b 
2,335 ± 713b 
Table 3: Effects of COX-1 and COX-2 Inhibition on PGI2 Release. 
The average release of PGF2α (stable metabolite of PGI2) ± standard error from each 
group in response to high VP-stimulation (10-6M), high VP+SC-560 (COX-1 inhibitor 
10-7M), or high VP+NS-398 (COX-2 inhibitor; 10-5M). Mean values without common 
script are significantly different (.001≤P≤0.05).   
 
 
 
4.3.1 Thromboxane A2  
4.3.1.1 Basal and VP-Stimulated TxA2 Release 
 Basal release of TxA2 from aortic sections was similar in all groups (Int-F (22.4 
± 3.0 pg/mg ring wt/45 min, OvX-F (14.3 ± 3.7 pg/mg), OvX-ER-F (23.7 ± 3.8 pg/mg), 
and M (18.02 ± 3.4 pg/mg) (P=0.31)). VP-stimulated TxA2 release was increased 
significantly in Int-F by 261% (22.4 ± 3.0 to 58.5 ± 9.8 pg/mg) and in OvX-ER-F by 
298% (23.7 ± 3.8 to 70.6 ± 7.3 pg/mg) (P<0.05). (Table 4, Figure 5).  
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Figure 6: Basal TxA2 Release. 
Basal release of TxA2 (measured as the stable metabolite TxB2) from aorta in rats. Bars 
are means ± S.E. Mean values did not differ significantly between groups (P≥ 0.05).  
 
 
 
Group                            TxA2 (pg/mg ring wt./45 min) 
                            Basal                        VP (10-6 M) 
 
Int-F (n=6) 
  
22.4 ± 3.0a 
 
58.5 ± 9.8b 
OvX-F (n=6)  14.3 ± 3.7a 30.7 ± 7.3a 
OvX-ER-F (n=7)  23.7 ± 3.8a 70.6 ± 7.3b 
Male (n=6)  18.0 ± 3.4a 30.3 ± 4.2a 
Table 4: Basal and VP-Stimulated Release of TxA2. 
Basal and VP-stimulated release of TxA2 (measured as stable metabolite Txβ2) from Int-
F, OvX-F, OvX-ER-F, and Male rat aortas. Values are means ± SE (n, no. of animals). 
Mean values without common script are significantly different (.001≤P≤0.05). VP 
stimulation increased TxA2 release significantly in Int-F and OvX-ER-F (P<0.05).  
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Figure 7: Basal and VP-Stimulated TxA2 Release. 
Release of TxA2 (measured as the stable metabolite TxB2) in response to VP-stimulation 
(10-6M) from aorta in rats. Bars are means ± S.E. VP stimulation in Int-F and OvX-ER-F 
increased TxA2 release significantly more than OvX-F and M (P<0.05). Mean values 
without common script are significantly different (.001≤P≤0.05). 
 
 
4.3.1.2 Effects of COX-1 Inhibition on VP-Stimulated TxA2 Release 
 In the presence of COX-1 inhibitor SC-560 (10-7M), TxA2 release in response to 
VP was significantly reduced by 73% in Int-F (15.9 vs. 58.5 pg/mg), 60% in OvX-F 
(12.2 vs. 30.7 pg/mg), 61% in OvX-ER-F (34.7 vs. 70.3 pg/mg) and 82% in M (5.6 vs. 
30.3 pg/mg). In OvX-ER-F and M, inhibition of TxA2 with SC-560 was significantly 
different (P<0.05) (Figure 6). 
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4.3.1.3 Effects of COX-2 Inhibition on VP-Stimulated TxA2 Release 
 In the presence of COX-2 inhibitor NS-398 (10-5), TxA2 release in response to 
VP was reduced significantly by 89% in Int-F (6.4 vs. 58.5 pg/mg ring wt./45 min.), 
65% in OvX-F (10.7 vs. 30.7 pg/mg), 86% in OvX-ER-F (9.6 vs. 70.3 pg/mg), and 79% 
in M (6.2 vs. 30.3 pg/mg). There was no differences between groups in response to 
COX-2 inhibition (P>0.05) (Figure 7).    
 
4.3.1.4 TxA2 Release in Response to COX-1 versus COX-2 Inhibition 
 The effects of specific COX-1 and COX-2 inhibitors, SC-560 and NS-398, 
respectively, on TxA2 release, were investigated in the aorta of M and F rats. Release of 
TxA2 was similar in the presence of SC-560 in all groups. Release of TxA2 was similar 
in the presence of NS-398 in all groups. Inhibition of TxA2 release by SC-560 and NS-
398 did not differ in in Int-F (73% and 89%), OvX-ER-F (61% and 86%), OvX-F (60% 
and 65%) or M (82% and 79%) rat aorta. (P>0.05) (Table 5, Figure 7).  
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Group 
(n≥6) 
TxA2 (pg/mg ring wt./45 min) 
 
High VP (10-6M)          SC-560 (10-7M)        NS-398 (10-5M) 
 
Int-F 58.5±9.8a 15.9±5.1c,d  6.4±2.3c,d 
OvX-F 30.7±7.3b 12.2±3.6c,d 10.7±3.7c,d 
OvX-ER-F 
M 
70.3±7.3a 
30.3±4.2b 
34.7±8.3c 
5.6±1.1d 
9.6±1.8d 
6.2±1.9c,d 
Table 5: Effects of COX-1 and COX-2 Inhibition on TxA2 Release. 
The average TxA2 release from each group in response to high VP-stimulation (10
-6M), 
high VP+SC-560 (COX-1 inhibitor 10-7M), or high VP+NS-398 (COX-2 inhibitor; 10-
5M). 
 
 
 
Figure 8: Effects of COX-1 and COX-2 Inhibition on VP-Stimulated TxA2 Release. 
Release of TxA2 (measured as the stable metabolite 6-keto-PGF1α) in response to COX-2 
inhibition with NS-398 (10-5M) + VP-stimulation (10-6M) from aorta in rats. Bars are 
means ± S.E. Mean values without common scripts are significantly different 
(.001≤P≤0.05).   
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4.4 Effects of Calphostin C, Ridogrel, Furegrelate, and Dazoxiben on Prostanoid 
Release 
4.4.1 Prostacyclin I2 
VP-stimulated release of PGI2 (4,016 ± 523 pg/mg ring wt./45 min.) was not 
significantly affected by pretreatment with the PKC inhibitor, Calphostin C (3,164 ± 593 
pg) in male rat aortic sections. Similarly, Ridogrel, a combined thromboxane synthase 
inhibitor and thromboxane receptor antagonist, and Furegrelate, a thromboxane synthase 
inhibitor, did not significantly affect the release of PGI2. (Figure 9, Table 6). Dazoxiben, 
a TxS inhibitor, increased the release of PGI2 significantly (0.001≤P≤0.05) (Figure 10). 
 
 
4.4.2 Thromboxane A2  
VP-stimulated release of TxA2 (20.1 ± 2.5 pg/mg ring wt./45 min.) was 
significantly increased by 228% in the presence of the PKC inhibitor, Calphostin C (46.0 
± 8.0 pg), in male rat aortic rings (P=0.005). Conversely, Ridogrel, a combined TxS 
inhibitor and TP receptor antagonist (5.2 ± 0.8 pg), and Furegrelate, a TxS inhibitor (6.5 
± 0.7 pg), both attenuated the release of TxA2 in aortic rings in a similar manner (74% 
and 68% reduction, respectively) (P≤.0001) (Table 6, Figure 11). Dazoxiben 
significantly attenuated the release of TxA2 in male aortic rings (0.001≤P≤0.05) (Figure 
12). 
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Group 6-ketoPGF1α                                       
(pg/mg ring wt./45 min) 
TxB2                                                
(pg/mg ring wt./45 min) 
VP (10-6M) 4,016±523a 20.1±2.5b 
Calphostin C (10-6M) 3,164±593a 46.0±8.0c 
Ridogrel (10-5M) 3,263±513a 5.2±0.8d 
Furegrelate (50µM) 4,657±552a 6.5±0.7d 
Table 6: Effects of Calphostin, Ridogrel and Furegrelate on PGI2 and TxA2 Release. 
VP-Stimulated release of 6-keto-PGF1α (stable metabolite of PGI2) and TxB2 (stable 
metabolite of TxA2) in response to Calphostin C (10
-6M), Ridogrel (10-5M), or 
Furegrelate (50µM) in the aorta of male rats. 
 
 
 
 
Figure 9: Effects of Calphostin, Ridogrel, and Furegrelate on PGI2 Release. 
VP-stimulated release of 6-keto-PGF1α (stable metabolite of PGI2) in response to 
Calphostin C (10-6M), Ridogrel (10-5M), or Furegrelate (50µM) in the aorta of male rats. 
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Figure 10: Effects of Dazoxiben (50 µM) on PGI2 Release. 
VP-stimulated release of 6-keto-PGF1α (stable metabolite of PGI2) in response to 
Dazoxiben (50 μM) in the aorta of male rats. DAZ significantly increased the release of 
PGI2 (.001≤P≤0.05). Bars are means ± S.E.   
 
 
 
 
Figure 11: Effects of Calphostin, Ridogrel, and Furegrelate on TxA2 Release. 
VP-Stimulated release of TxB2 (stable metabolite of TxA2) in response to Calphostin C 
(10-6M), Ridogrel (10-5M), or Furegrelate (50µM) in the aorta of male rats. Bars are 
means ± S.E. (Mean values without common script are significantly different 
(.001≤P≤0.05). 
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Figure 12: Effects of Dazoxiben (50µM) on TxA2 Release. 
VP-stimulated release of TxA2 in response to Dazoxiben (50 μM) in the aorta of male 
rats. DAZ significantly decreased the release of TxA2 (.001≤P≤0.05). Bars are means ± 
S.E.   
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CHAPTER V  
DISCUSSION AND SUMMARY 
 
 This study investigated the effects of selective COX-1 and COX-2 inhibitors and 
specific prostanoid pathway inhibitors on the production of vascular prostanoids, 
specifically thromboxane and prostacyclin, in the aortas of male and female Sprague-
Dawley rats. The central hypothesis tested was that selective inhibition of COX-1 would 
reduce the release of TxA2 to a greater extent than PGI2 in the aorta, whereas selective 
COX-2 inhibition would decrease the release of PGI2 more than TxA2.  We further 
hypothesized that estrogen would enhance the production of prostanoids derived from 
COX-2, but not those derived from COX-1. Furthermore, it was hypothesized that TxA2 
has an inhibitory effect on PGI2 synthesis, mediated by a TP receptor mediated signaling 
pathway that inhibits PGI2 synthase. Indeed, the selective inhibition of COX-1 and 
COX-2 in male and female rat aortas revealed that a clear sexual dimorphism exists in 
the synthesis of PGI2 and TxA2 through the COX-1 and COX-2 pathways. VP-
stimulated TxA2 release was significantly increased in aortas from both female and male 
rats; however, VP-stimulated PGI2 release was significantly increased only in female 
rats.  
 Selective inhibition of COX-1 with SC-560 and inhibition of COX-2 with NS-
398 significantly reduced VP-stimulated release of PGI2 in female rats, but not in male 
rats. There was no difference in the inhibition of PGI2 by SC-560 or NS-398 between 
any groups. Selective inhibition of COX-1 with SC-560 and inhibition of COX-2 with 
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NS-398 significantly reduced VP-stimulated TxA2 release in the aortas of both male and 
female rats. Furthermore, inhibition of VP-stimulated TxA2 release with NS-398 was 
greater than with SC-560 in estrogen-replaced OvX-ER-F females while inhibition with 
SC-560 was similar among all groups.  
 This study also investigated the mechanism by which TxA2 depresses PGI2 
synthesis. Although Dazoxiben, TxS inhibitor proved a marked increase in PGI2 release 
while depressing TxA2 release, inhibition of PKC (with Calphostin C) did not produce a 
significant increase in PGI2 release. Similarly, there were no significant increases in 
PGI2 release after treatment with a TP receptor antagonist (Furegrelate) or with the 
combined TP receptor antagonist and TxS inhibitor (Ridogrel).   
 
5.1 Estrogen Levels 
 In order to determine the role of estrogen in the regulation of PGI2 and TxA2 
release via the cyclooxygenase isoforms, estrogen-intact female rats (Int-F) , 
ovariectomized rats (OvX-F), and estrogen-replaced OvX-F rats (OvX-ER-F) were 
included in this study.  Plasma 17β–estradiol levels were measured in all rats included in 
the present study.  Ovariectomy reduced the plasma 17β–estradiol concentrations to a 
similar level found in M, whereas estrogen replacement in ovariectomized female rats 
restored plasma 17β–estradiol to similar concentrations found in Int-F. Estrogen levels in 
Int-F were lower than OvX-ER-F because the rats were sacrificed on random days 
within the estrus cycle. OvX-ER-F rats maintain high levels of circulating estrogen from 
the estradiol replacement treatment. It is normal for cycling Int-F to produce estrogen 
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levels in range 19 ± 5pg/mL plasma at the onset of estrus to 284 ± 25pg/mL plasma 
during proestrus, thus a discrepancy between Int-F and OvX-ER-F estrogen levels is to 
be expected (64). The concentrations of plasma 17β–estradiol measured in the present 
study were similar to age matched male and female animals in previous studies (8, 73).  
 
5.2 Basal and VP-Stimulated Release of PGI2 and TxA2  
 In the present study, basal release of PGI2 and TxA2 was similar in all groups. In 
females, stimulation with vasopressin significantly increased the release of PGI2 and 
TxA2; however, in males TxA2 was also increased. VP-stimulated release of PGI2 was 
increased more in Int-F and OvX-ER-F compared to M and OvX-F. Similarly, VP-
stimulated release of TxA2 was increased more in Int-F and OvX-ER-F compared to M 
and OvX-F rats. This finding was not surprising, as it is consistent with previous studies 
that reported a three-fold increase in response to VP by the female rat aorta (4, 43, 68). 
The evidence from the present study and previous studies suggest that the sexual 
dimorphism in the systemic vasculature is dependent upon the presence of estrogen, a 
potent ovarian hormone in females. Although these studies reported that the mechanism 
responsible for the increase in prostanoid release is the effect of estrogen to upregulate 
COX-2, TxS and TP receptor expression, the studies did not investigate the relative 
contributions of COX-1 vs. COX-2 on prostanoid release. 
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5.3 Effects of Selective COX-1 and COX-2 Inhibition on PGI2 Release from the Aorta 
 To determine the role of the different COX enzymes on the release of PGI2 in 
female and male rat aorta, the selective COX-1 inhibitor SC-560 was used in Int-F, 
OvX-F and OvX-ER-F rats. COX-1 is well documented to be constitutively expressed 
throughout the body and serves as a housekeeping enzyme. SC-560 reduced VP-
stimulated PGI2 release similarly in Int-F by 56% and by 54% in M.  These results 
demonstrate an explicit role for COX-1 in PGI2 synthesis; however, they also suggest 
that estrogen does not affect the contribution of COX-1 to PGI2 release. It is not 
surprising that estrogen affected COX-1 similarly in all groups because COX-1 is known 
as the constitutive isoform of the cyclooxygenase enzyme and was not altered by 
estrogen in previous studies (45).  
 The present study suggests COX-1 is a major contributor to PGI2 synthesis in the 
rat aorta. Despite the dogma that COX-2 is solely responsible for PGI2 synthesis, 
multiple studies have also reported a significant role for COX-1 synthesis of PGI2 in the 
vasculature (37, 38, 44). It is crucial that COX-1 plays a role in the synthesis of PGI2 in 
the vasculature to counterbalance the presence of other vasoconstricting prostanoids, 
such as TxA2. This may be an important step toward disproving the theory that aspirin 
offers cardiovascular protection through selective COX-1 inhibition. 
 The COX-2 isoform is constitutively expressed in some tissues throughout the 
body such as kidney, lung, spinal cord, heart and in the rat aorta (43).  Unlike COX-1, 
COX-2 is also an inducible form of the cyclooxygenase enzyme, and is known to be 
mediated by inflammatory agents, mitogens and hormones such as estrogen (19, 43). 
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The present study found that VP-stimulated PGI2 release was significantly reduced by 
COX-2 inhibition with NS-398 in all groups by an average of 71% (76% in Int-F and 
53% in M). This indicates that COX-2 contributes significantly to the synthesis of PGI2 
in both the male and female rat aorta.  
 VP-stimulated PGI2 release in female rats (Int-F and OvX-ER-F) was reduced to 
similar levels in estrogen-depleted rats (M and OvX-F) by COX-1 and COX-2 
inhibition. This is significant because if COX-2 inhibition reduces the protective 
prostaglandins released by the vasculature similarly to COX-1 inhibition in females, 
non-selective NSAIDs may predispose females to cardiovascular risks. In estrogen-
depleted rats (M and OvX-F), inhibition of either COX isoform reduced PGI2 release 
similarly. Therefore, COX-1 selective NSAIDs (such as aspirin) reduce the synthesis of 
PGI2 similarly to non-selective NSAIDs.  
 
5.4 Effects of Selective COX-1 and COX-2 Inhibition on TxA2 Release from the Aorta 
The COX-1 isoform is widely known to be present in platelets as well as 
constitutively expressed in most cell types. Historically, COX-1 was believed to mediate 
TxA2 synthesis in the platelets, causing platelet aggregation and vasoconstriction. 
However, more recent studies have revealed that the vascular wall is also a 
physiologically relevant source of TxA2 (25, 43). In the present study, inhibition of VP-
stimulated TxA2 release with SC-560 caused a greater reduction in males than in 
ovariectomized, estrogen replaced females. Interestingly, inhibition with NS-398 
significantly reduced TxA2 release similarly in all groups, which strongly suggests that 
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both COX-1 and COX-2 contribute to the release of TxA2 in both the male and female 
rat aorta, although COX-1 may play a larger role in TxA2 release in males than females.   
Aspirin, a widely used relatively specific COX-1 inhibitor, is recommended to 
reduce the risk of negative thrombotic events by reducing TxA2 in the vasculature while 
preserving the synthesis of vasoprotective PGI2. Recent studies have indicated that both 
TxA2 and PGI2 are significantly synthesized via COX-1 in the vasculature, which was 
confirmed in the present study. Additionally, this study also established that COX-1 and 
COX-2 both independently contribute to the production of a significant amount of PGI2 
and TxA2 in the systemic vasculature. This suggests that the mechanism by which aspirin 
confers its cardioprotective effects is not by solely reducing TxA2, but rather an unknown 
mechanism that alters the sensitive balance of PGI2 and TxA2 in the vasculature. 
Furthermore, it has been suggested that COX-2 selective inhibitors are systematically 
more potent in inhibiting the endothelial production of PGI2 than the platelet production 
of thromboxane A2 (51). This would support the theory that the use of COX-2 inhibitory 
drugs may increase the risk of thrombotic vascular events, however, the present study 
found no difference in the production of PGI2 versus TxA2 by COX-1 vs. COX-2. Thus, 
the apparently deleterious effects of COX-2-selective inhibitory drugs on thrombotic 
events may result from a different mechanism, independent of PGI2 inhibition.  
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5.5 Effects of Calphostin, Ridogrel, Furegrelate, and Dazoxiben on PGI2 and TxA2 
Release 
Within the vascular system, PGI2, TxA2, and their respective receptors are known 
to interact and mediate the release of these vascular mediators. PGI2 and TxA2 are 
derived from the same intermediate PGH2, via the action of their respective synthase 
enzymes, prostacyclin synthase and TxS. Because the balance between PGI2 and TxA2 is 
critical for maintaining homeostasis in the vasculature, altering the production of one of 
these mediators can cause significant effects. Previous studies reported that inhibition of 
TxS causes accumulation of the intermediate PGH2, thus enhancing PGI2 production 
(43). PGI2 has been shown to depress TxA2 production in the cardiovascular system, 
causing an overall vasodilatory effect (17). Conversely, TxA2 has been shown to 
attenuate PGI2 within endothelial cells of the vasculature, leading to increased 
vasoconstriction and platelet aggregation (43). Several mechanisms may be involved in 
pathway interaction between PGI2 and TxA2. Cross-talk between the two prostanoids 
and their receptors may be a result of receptor heterodimerization, overlapping genetic 
response elements for the receptors, or activation/inactivation of intracellular proteins 
involved within each pathway by the opposing prostanoid (5, 15). 
The present study investigated the role of PKC, TxS and the TP receptor in the 
interactions between the PGI2 and TxA2 pathways. Because the balance of PGI2 and 
TxA2 is critical for maintaining homeostasis in the vasculature, altering the production of 
one of these mediators can cause significant effects. Specifically, the present study 
investigated the mechanism by which TxA2 regulates PGI2 in vivo.   
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PGI2 and TxA2 are derived from the same intermediate PGH2, and their 
respective synthase enzymes, prostacyclin synthase and TxS. Previous studies reported 
that inhibition of TxS causes accumulation of the intermediate PGH2, thus enhancing 
PGI2 production (43). Furthermore, it has been suggested that another form of cross-talk 
between the pathways occurs by TxA2 down-regulating PGI2 release, because the TXS 
inhibitor Dazoxiben increases PGI2 release in the rat aorta (45). It was hypothesized that 
through the downstream effects of PKC-mediated nitrosylation of tyrosine residues on 
PGI synthase, TxA2 decreases PGI2 production in the vascular wall. These mechanisms 
were investigated using Calphostin C, a PKC inhibitor, Ridogrel, a combined TxS 
inhibitor and TP receptor antagonist, Furegrelate, a TP receptor antagonist, and 
Dazoxiben, a TxS inhibitor. Interestingly, despite Ridogrel and Furegrelate significantly 
decreasing TxA2 release, neither of these inhibitors significantly attenuated PGI2 release 
in the aorta. Dazoxiben markedly attenuated TxA2 release, which was not surprising. In 
previous studies using Dazoxiben on PGI2 production in rat aorta (45) and human blood 
vessels (3), DAZ increased prostacyclin production. The authors suggested that 
inhibition of TxS made endoperoxides PGG2 and PGH2 more readily available for 
conversion to PGI2 (13). However, the relative increase in PGI2 is far greater in 
comparison to the amount of PGG2 and PGH2 that would be made available by TxS 
inhibition. One possible explanation for the extreme increase in PGI2 is the chemical 
structure of Dazoxiben, which is very similar to inhibitors of long chain fatty acyl COA 
synthetase, which results in increased release of arachidonic acid from cells. Thus, 
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Dazoxiben could inhibit TxS and release more arachidonic acid from cells, resulting in 
the substantial increase in PGI2. 
Calphostin did not alter PGI2 release either; however, it did cause a 228% 
increase in release of TxA2. The mechanism by which Calphostin increased TxA2 release 
is unclear. It is possible that PKC is involved in homologous desensitization (negative 
feedback loop) of TxA2, therefore inhibition of PKC causes increased release of TxA2. In 
a previous study, PKC knockout mice exhibited shorter times to occlusion and shorter 
bleeding times in tail bleeding experiments suggesting that PKC negatively regulates 
TxA2, but may not affect PGI2 (9).  
The present study also used the TP receptor antagonist Furegrelate, and the 
combined TxS inhibitor and TP receptor antagonist, Ridogrel, to clarify the effects of 
TxA2 on PGI2 synthesis.   Despite the observation that Ridogrel and Furegrelate both 
significantly decreased TxA2, neither of these inhibitors significantly affected the release 
of PGI2 in the aorta. However, TxS inhibitor, Dazoxiben (DAZ) showed inhibition of 
TxS and reduction of TxA2 production enhanced the production of PGI2. This is similar 
to previous studies which suggest that TxS inhibitors enhance the production of PGI2 
(43).  Ridogrel and Furegrelate decreased TxA2 levels to concentrations similar to those 
with the use of DAZ; however they did not have a similar effect on PGI2. This 
discrepancy is puzzling, and may be of interest for future research.  
Although the TP receptor antagonists did not show increase in PGI2, the effects 
may be of clinical relevance.  The balance of TxA2 and PGI2 is complex and sensitive. 
Blocking the TP receptor may potentially reduce the negative cardiovascular effects 
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while not altering the release of PGI2 (11). This may be beneficial in situations where 
only mild effects of PGI2 are desired, particularly PGI2’s vasodilatory effect may be 
desired, but its antiplatelet effect may not. The EC50 for inhibition of platelet aggregation 
by PGI2 was found to be 1.3nM  in isolated uterine artery, while the EC50 for 
vasodilation by PGI2 was found to be 10
-8M in bovine coronary artery (40, 62).  
Therefore, it is unlikely that one could regulate the amount of PGI2 to produce one effect 
without the other. 
In conclusion, although for years the dogma was that the PGI2/TxA2 balance can 
be altered by COX-2 specific drugs to cause negative cardiovascular effects, more recent 
studies in addition to the present study, suggest otherwise. It was found that COX-1 and 
COX-2 both mediate significant production of both PGI2 and TxA2 similarly in the rat. 
Furthermore, when estrogen is present, a marked sexual dimorphism exists in the 
production of both TxA2 and PGI2. The production of both prostanoids was enhanced in 
the presence of estrogen. Further, there was no difference in the inhibition of the 
prostanoids when estrogen was not present.  In the presence of estrogen, the selective 
COX-2 inhibitor seemed to attenuate TxA2 production more than PGI2. This suggests 
that in females, it is unlikely that COX-2 inhibitors would elevate the risk of thrombosis, 
and may be useful in determining the guidelines for NSAIDs usage in women. 
Furthermore, at the doses of COX-1 and COX-2 inhibitors used, the present study does 
not support the existing dogma that COX-2 selective inhibitors increase the risk of 
cardiovascular disease by tipping the balance between TxA2/PGI2 in favor of TxA2. 
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